DongKook Pharmaceutical Co. Ltd (086450) — Capital Reinvestment Ratio
DongKook Pharmaceutical Co. Ltd (086450) has a Capital Reinvestment Ratio of 0.61x as of December 2025, meaning it reinvests 1% of its operating cash flow (₩23.53 Billion) in capital expenditures (₩14.42 Billion). See 086450 net asset quality score to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
DongKook Pharmaceutical Co. Ltd Capital Reinvestment Ratio (2013–2025)
This chart tracks DongKook Pharmaceutical Co. Ltd's Capital Reinvestment Ratio across 13 annual periods. Check 086450 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for DongKook Pharmaceutical Co. Ltd (2013–2025)
Year-by-year Capital Reinvestment Ratio for DongKook Pharmaceutical Co. Ltd from 2013 to 2025. For live market cap and broader valuation context, see DongKook Pharmaceutical Co. Ltd market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.67x | ₩68.76 Billion | ₩46.00 Billion | ▲ +65.2% |
| 2024 | 0.40x | ₩76.09 Billion | ₩30.80 Billion | ▼ -57.0% |
| 2023 | 0.94x | ₩41.79 Billion | ₩39.35 Billion | ▼ -24.8% |
| 2022 | 1.25x | ₩40.91 Billion | ₩51.23 Billion | ▲ +9.6% |
| 2021 | 1.14x | ₩44.65 Billion | ₩51.01 Billion | ▲ +70.5% |
| 2020 | 0.67x | ₩59.11 Billion | ₩39.61 Billion | ▲ +85.3% |
| 2019 | 0.36x | ₩69.48 Billion | ₩25.13 Billion | ▼ -84.1% |
| 2018 | 2.27x | ₩33.21 Billion | ₩75.46 Billion | ▲ +457.8% |
| 2017 | 0.41x | ₩28.66 Billion | ₩11.67 Billion | ▲ +66.9% |
| 2016 | 0.24x | ₩39.41 Billion | ₩9.62 Billion | ▼ -30.9% |
| 2015 | 0.35x | ₩27.14 Billion | ₩9.60 Billion | ▼ -40.8% |
| 2014 | 0.60x | ₩22.74 Billion | ₩13.59 Billion | ▲ +197.2% |
| 2013 | 0.20x | ₩19.86 Billion | ₩3.99 Billion | — |